Northfield positions itself to raise capital

Northfield Laboratories Inc., a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, announced on 9/1/06 that it has filed a shelf registration statement with the Securities and Exchange Commission. Once effective, the shelf registration would allow the Company to offer and sell up to $100 million of its securities from time to time. The terms of any such future offerings would be established at the time of the offering.

Oddly, Google Alerts just tossed this in my box this week